[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-detail-31498":3,"doc-seo-31498":27},{"code":4,"msg":5,"data":6},0,"success",{"doc_id":7,"user_id":8,"nickname":9,"user_avatar":10,"doc_module":4,"category_id":11,"category_name":12,"doc_title":13,"doc_description":14,"file_id":15,"file_url":16,"file_type":17,"file_size":18,"view_count":4,"is_deleted":4,"is_public":19,"is_downloadable":19,"audit_status":19,"page_count":20,"language":21,"language_code":22,"table_of_contents":23,"faqs":24,"seo_title":13,"seo_description":14,"update_tm":25,"read_time":26},31498,962075114101,"Seraphina","https://ap-avatar.wpscdn.com/avatar/e000253a75eb197efd?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780044092746381165",7,"Healthcare","Roads and detours for CAR T cell therapy in autoimmune diseases","Engineered chimeric antigen receptor (CAR) T cells are designed to direct a patient’s own T cells against defined antigens using an antibody-derived scFv plus transmembrane and intracellular TCR CD3ζ and co-stimulatory signalling domains. FDA-approved CAR T products targeting CD19 or BCMA have shown strong clinical efficacy in lymphoid cancers, with manageable toxicity. Autoimmune diseases involve heterogeneous B-cell-driven mechanisms, where anti-CD20 rituximab often yields inconsistent benefit; CAR T therapy offers proliferative and tissue-migratory advantages. Robust oncology data now informs CAR T development for autoimmune settings.","cbCaim1j8Dn5HRlV","https://ap.wps.com/l/cbCaim1j8Dn5HRlV","pdf",2029727,1,20,"English","en","# Introduction\n# CAR T cell design and clinical success in oncology\n# Why CAR T approaches are relevant to autoimmune disease\n# Autoimmune disease biology and limits of anti-CD20 therapy\n# Conceptual advantages of CAR T over monoclonal antibodies\n# Preclinical proof-of-concept and therapeutic targeting\n# Status of CAR T cell therapies in oncology","[{\"question\":\"How do CAR T cells recognize and kill target cells?\",\"answer\":\"CARs display an extracellular scFv that determines antigen specificity, while transmembrane and intracellular domains (including TCR CD3ζ and co-stimulatory signalling) activate the CAR T cell and initiate proliferation. This enables targeted recognition and downstream effector responses.\"},{\"question\":\"Which CAR T targets have been approved for clinical use and for what cancers?\",\"answer\":\"Six CAR T cell therapies are approved by the US FDA: four targeting CD19 for B cell lineage leukaemia and/or lymphoma, and two targeting BCMA for multiple myeloma. Clinical development also includes late-phase evaluation of CAR T therapies targeting CD22.\"},{\"question\":\"Why might CAR T therapy work for autoimmune diseases despite inconsistent rituximab results?\",\"answer\":\"Autoimmune pathology often depends on B-cell lineages that produce autoantibodies and act as antigen-presenting cells. Rituximab anti-CD20 has produced inconsistent clinical effects, while CAR T cells offer advantages over injected monoclonal antibodies: in vivo proliferation and active migration into tissues to deplete tissue-resident B cells.\"}]",1779570166,50,{"code":4,"msg":28,"data":29},"ok",{"site_id":30,"language":22,"slug":31,"title":13,"keywords":32,"description":14,"schema_data":33,"social_meta":84,"head_meta":86,"extra_data":88,"updated_unix":25},105,"roads-and-detours-for-car-t-cell-therapy-in-autoimmune-diseases","",{"@graph":34,"@context":83},[35,52,66],{"@type":36,"itemListElement":37},"BreadcrumbList",[38,42,46,49],{"item":39,"name":40,"@type":41,"position":19},"https://docshare.wps.com","Home","ListItem",{"item":43,"name":44,"@type":41,"position":45},"https://docshare.wps.com/document/","Document",2,{"item":47,"name":12,"@type":41,"position":48},"https://docshare.wps.com/document/healthcare/",3,{"item":50,"name":13,"@type":41,"position":51},"https://docshare.wps.com/document/roads-and-detours-for-car-t-cell-therapy-in-autoimmune-diseases/31498/",4,{"url":50,"name":13,"@type":53,"author":54,"headline":13,"publisher":56,"fileFormat":59,"description":14,"dateModified":60,"datePublished":60,"encodingFormat":59,"isAccessibleForFree":61,"interactionStatistic":62},"DigitalDocument",{"name":9,"@type":55},"Person",{"url":39,"name":57,"@type":58},"DocShare","Organization","application/pdf","2026-05-23",true,{"@type":63,"interactionType":64,"userInteractionCount":4},"InteractionCounter",{"@type":65},"ViewAction",{"@type":67,"mainEntity":68},"FAQPage",[69,75,79],{"name":70,"@type":71,"acceptedAnswer":72},"How do CAR T cells recognize and kill target cells?","Question",{"text":73,"@type":74},"CARs display an extracellular scFv that determines antigen specificity, while transmembrane and intracellular domains (including TCR CD3ζ and co-stimulatory signalling) activate the CAR T cell and initiate proliferation. This enables targeted recognition and downstream effector responses.","Answer",{"name":76,"@type":71,"acceptedAnswer":77},"Which CAR T targets have been approved for clinical use and for what cancers?",{"text":78,"@type":74},"Six CAR T cell therapies are approved by the US FDA: four targeting CD19 for B cell lineage leukaemia and/or lymphoma, and two targeting BCMA for multiple myeloma. Clinical development also includes late-phase evaluation of CAR T therapies targeting CD22.",{"name":80,"@type":71,"acceptedAnswer":81},"Why might CAR T therapy work for autoimmune diseases despite inconsistent rituximab results?",{"text":82,"@type":74},"Autoimmune pathology often depends on B-cell lineages that produce autoantibodies and act as antigen-presenting cells. Rituximab anti-CD20 has produced inconsistent clinical effects, while CAR T cells offer advantages over injected monoclonal antibodies: in vivo proliferation and active migration into tissues to deplete tissue-resident B cells.","https://schema.org",{"og:url":50,"og:type":85,"og:title":13,"og:site_name":57,"og:description":14},"article",{"robots":87,"canonical":50},"index,follow",{"doc_id":7,"site_id":30}]